BLS Pharmaceuticals

BLS Pharmaceuticals is a clinical-stage biotechnology company focused on the development of oral enzyme replacement therapies for rare metabolic disorders. The company's lead candidate, BLS-M01, is an oral, non-absorbable formulation of phenylalanine ammonia-lyase (PAL) intended for the treatment of Phenylketonuria (PKU). By targeting the degradation of phenylalanine within the gastrointestinal tract, BLS-M01 aims to lower blood phenylalanine levels without the need for systemic absorption or frequent injections. The company is headquartered in Lexington, Massachusetts, and continues to advance its pipeline to address significant unmet needs in the rare disease space. Its approach leverages protein engineering to create stable enzymes capable of surviving the digestive environment.